Home Featured Page 192

Featured

Latest

The Best Psychedelic Education Does Not Look Psychedelic

Pα+ Psychedelic Bulletin #230: Pharma Ramps Up Ad Spend on Psychedelic Keywords; ARPA-H’s Ibogaine Funding; Psychedelics in Medicaid?

A Closer Look at Definium’s Phase 3 LSD for GAD Readout

Psychedelic Bulletin: Numinus to Enter U.S. Clinics Market; Mydecine Announces Reverse...

MindMed Collaborator Dr. Matthias Liechti to Present Topline Clinical Trial Results...

Numinus Wellness Inc. Reports Q2 2022 Results

Psychedelic Bulletin: Psychedelics X Big Pharma; $23m Round for At-Home Ketamine...

Psychedelic Research Bulletin: March 2022

MYND Life Sciences Announces $3.5 Million Share Offering

Cybin Partners with Clinilabs Drug Development Corporation for Phase 1/2a Trial...

PT313 – Christine Calvert, LCDC – Holotropic Breathwork, Ethics, and Dying...

Psychedelic Bulletin: Psychedelics X Big Pharma; $23m Round for At-Home Ketamine...

MYND Life Sciences Announces $3.5 Million Share Offering

EDITOR PICKS

The Best Psychedelic Education Does Not Look Psychedelic

Pα+ Psychedelic Bulletin #230: Pharma Ramps Up Ad Spend on Psychedelic...

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

Pα+ Library: Psychedelic REMS

The Best Psychedelic Education Does Not Look Psychedelic

Pα+ Psychedelic Bulletin #230: Pharma Ramps Up Ad Spend on Psychedelic Keywords; ARPA-H’s Ibogaine Funding; Psychedelics in Medicaid?

A Closer Look at Definium’s Phase 3 LSD for GAD Readout

Who Gets to Heal?

Psychedelic Bulletin: Numinus to Enter U.S. Clinics Market; Mydecine Announces Reverse...

MindMed Collaborator Dr. Matthias Liechti to Present Topline Clinical Trial Results...

Numinus Wellness Inc. Reports Q2 2022 Results

Psychedelic Bulletin: Psychedelics X Big Pharma; $23m Round for At-Home Ketamine...

Psychedelic Research Bulletin: March 2022

MYND Life Sciences Announces $3.5 Million Share Offering

Cybin Partners with Clinilabs Drug Development Corporation for Phase 1/2a Trial...

PT313 – Christine Calvert, LCDC – Holotropic Breathwork, Ethics, and Dying...

Psychedelic Bulletin: Psychedelics X Big Pharma; $23m Round for At-Home Ketamine...

MYND Life Sciences Announces $3.5 Million Share Offering

EDITOR PICKS

Pα+ Library: Psychedelic REMS

The Best Psychedelic Education Does Not Look Psychedelic

Pα+ Psychedelic Bulletin #230: Pharma Ramps Up Ad Spend on Psychedelic...

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY